A significant proportion of early graft occlusions after aortocoronary revascularization using autologous saphenous vein grafts (SVG) are due to mechanical and/or metabolic or biochemical endothelial lesions. The morphological examination of the endothelium, usually carried out using light microscopy or by various types of scanning electron microscopy (SEM), does not give any indication of the functioning of the endothelium (E). Functionally intact E is capable of producing endothelium-derived relaxing factor (EDRF); a practicable in vitro test is the relaxation of pre-contracted vein segments (VS) in response to acetylcholine (ACh) application. To study the effect of the solution used to rinse and store the SVG between removal and implantation on the functional characteristics of the E, we performed in vitro tests on macroscopically intact VS removed from the saphenous vein of 30 male patients who underwent elective CABG surgery. Isolated VS rings were incubated for 60 min in heparinized whole blood (HWB), Bretschneider's cardioplegic solution (HTK), human albumin solution (HAS), or Ringer's solution (RS) and compared with the results obtained immediately after the removal of untreated control samples (C) taken from the same patients. After equilibration in carbogen aerated Krebs-Henseleit solution and precontraction by 3 x 10(-7) M noradrenaline (NE), relaxation induced by 10(-6) M ACh was measured. Only the samples stored in HWB (13.4 +/- 0.4 mN) showed similar maximal contractions with NE to those in the control group (14.4 +/- 0.5 mN), i.e. all those segments which showed both contractions with NE and relaxation with ACh.(ABSTRACT TRUNCATED AT 250 WORDS)
The benefit of DDD(R) pacing is proven even in patients with intermittent atrial fibrillation. Atrial fibrillation developing during dual chamber pacemaker implantation creates a difficult problem. Maneuvers to reestablish a stable atrial rhythm often are required if atrial fibrillation sets in. This study was performed to determine if atrial lead placement can be performed with acceptable long-term results in the presence of atrial fibrillation. Twenty-one patients in whom atrial fibrillation developed during permanent pacemaker implantation were included in this study. In 12 patients, episodes of intermittent atrial fibrillation had been documented before the procedure. Screw-in leads were used in 15 patients and J-shaped passive fixation leads in 6 patients. All leads were bipolar. The intraoperative atrial fibrillation electrogram amplitudes ranged from 0.9 to 3.2 mV (mean 1.8 +/- 0.6 mV). One patient required lead revision due to a high atrial pacing threshold after conversion to SR. One patient remained in atrial fibrillation at 3-month follow-up. The other 20 patients converted to SR, 11 of whom had intermittent atrial fibrillation with successful mode switch activation. P wave amplitudes were 2.8 +/- .6 mV (range 1.4 to 4.0 mV) after conversion to SR. The mean atrial pacing threshold was 1.1 +/- 0.5 V (range 0.5 to 3.5 V). Placement of atrial leads in patients who develop atrial fibrillation during pacemaker implantation is feasible; fibrillatory electrogram amplitudes showed a good correlation with the atrial signal after conversion to an organized atrial rhythm (r = 0.698). Acceptable atrial pacing thresholds can be expected as well.
Pacing and sensing failure in apical right ventricular coil electrode PCD implantation due to ventricular scars or aneurysma may force the implanting surgeon to switch to more invasive procedures such as subxyphoidal pericardiotomy or thoracotomy for epimyocardial corkscrew electrode and for epicardial patch application. In order to avoid this more invasive operation in the most severely impaired patients, right ventricular outflow tract positioning of the RV electrode is suggested as an alternative RV electrode site for implantation. A study of four cases shows that this occasional procedure is a practicable method to avoid more invasive techniques. Excellent pacing, sensing, and defibrillation characteristics were obtained and application is relatively simple.
Intraoperative testing with several fibrillation/defibrillation episodes (FDEs) is routinely performed during defibrillator implantation. Testing is considered safe even in patients with severe cardiac impairment, provided the recovery timespans and number of FDEs are adapted to the individual patient. Myocardial lactate extraction (MLE) was examined in two testing protocols. In 30 patients with coronary artery disease defibrillator implantations were performed under intravenous anesthesia. A percutaneous catheter was positioned into the coronary sinus (CS) underfluoroscopy. Two groups were randomly formed: group A (n = 20, mean number of FDEs: 4.2/patient) with 2 minutes waiting time between FDEs, and group B (n = 10, mean number of FDEs 4.1/patients) with 10 minutes between FDEs. Defibrillation pulses were released 15 seconds after T wave shock induced fibrillation. To estimate MLE, arterial and CS blood samples were collected before and after each FDE. After the last FDE, samples were obtained after 5, 10, and up to 20 minutes. In group A, MLE fell from a baseline value of 29.6% +/- 3.6% before the FDEs to 7.8% +/- 5.4% immediately after the episodes. MLE recovered to 27.2% +/- 6.5% within 1 minute and overshot to 35.6% +/- 5.8% within 5 minutes. In group B, MLE decreased from 37.6% +/- 7.5% to 15.1% +/- 8.1% immediately after each FDE and rose to its original value (33.6 +/- 7.8) within the 5-minute recovery period. MLE decreased immediately after each FDE, and recovered within 1 minute even in poor left ventricular function. For full MLE recovery a 2-minute wait between episodes is sufficient, if the total number of FDEs does not exceed four.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.